Protagonist Therapeutics Past Earnings Performance
Past criteria checks 4/6
Protagonist Therapeutics has been growing earnings at an average annual rate of 24.8%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 68.6% per year. Protagonist Therapeutics's return on equity is 32.1%, and it has net margins of 52.8%.
Key information
24.8%
Earnings growth rate
31.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 68.6% |
| Return on equity | 32.1% |
| Net Margin | 52.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey
Oct 16Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't
Apr 13
Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise
Feb 25We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Dec 28We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Jul 04Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 20An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued
Feb 06We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate
Jun 15Protagonist: Too Many Red Flags
Jun 08Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%
May 11Protagonist Is Still Being Undervalued Like There's Real Risk
Feb 01Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth
Jan 04Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates
Aug 06Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year
Jun 19Protagonist Therapeutics closes $132M capital raise
Jun 18Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy
Jun 03This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet
May 21Protagonist EPS beats by $0.03, beats on revenue
May 04Revenue & Expenses Breakdown
How Protagonist Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 324 | 171 | 43 | 132 |
| 30 Jun 24 | 319 | 170 | 40 | 127 |
| 31 Mar 24 | 315 | 162 | 40 | 126 |
| 31 Dec 23 | 60 | -79 | 33 | 120 |
| 30 Sep 23 | 0 | -140 | 32 | 121 |
| 30 Jun 23 | 0 | -138 | 31 | 116 |
| 31 Mar 23 | 1 | -140 | 30 | 117 |
| 31 Dec 22 | 27 | -127 | 32 | 126 |
| 30 Sep 22 | 35 | -130 | 32 | 135 |
| 30 Jun 22 | 45 | -133 | 33 | 146 |
| 31 Mar 22 | 47 | -122 | 32 | 138 |
| 31 Dec 21 | 27 | -126 | 27 | 126 |
| 30 Sep 21 | 24 | -108 | 25 | 107 |
| 30 Jun 21 | 27 | -81 | 23 | 86 |
| 31 Mar 21 | 31 | -70 | 20 | 80 |
| 31 Dec 20 | 29 | -66 | 19 | 75 |
| 30 Sep 20 | 26 | -65 | 18 | 71 |
| 30 Jun 20 | 17 | -73 | 17 | 76 |
| 31 Mar 20 | 2 | -83 | 17 | 71 |
| 31 Dec 19 | 0 | -77 | 16 | 65 |
| 30 Sep 19 | 0 | -74 | 15 | 63 |
| 30 Jun 19 | 2 | -66 | 15 | 54 |
| 31 Mar 19 | 22 | -45 | 14 | 57 |
| 31 Dec 18 | 31 | -39 | 14 | 59 |
| 30 Sep 18 | 40 | -28 | 13 | 57 |
| 30 Jun 18 | 43 | -24 | 12 | 56 |
| 31 Mar 18 | 31 | -31 | 12 | 50 |
| 31 Dec 17 | 20 | -37 | 12 | 46 |
| 30 Sep 17 | 9 | -45 | 11 | 43 |
| 30 Jun 17 | 0 | -48 | 10 | 38 |
| 31 Mar 17 | 0 | -40 | 9 | 31 |
| 31 Dec 16 | 0 | -38 | 7 | 26 |
| 30 Sep 16 | 0 | -32 | 5 | 21 |
| 30 Jun 16 | 0 | -28 | 4 | 19 |
| 31 Mar 16 | 0 | -24 | 4 | 15 |
| 31 Dec 15 | 0 | -15 | 3 | 12 |
Quality Earnings: PTGX has high quality earnings.
Growing Profit Margin: PTGX became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PTGX has become profitable over the past 5 years, growing earnings by 24.8% per year.
Accelerating Growth: PTGX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: PTGX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: PTGX's Return on Equity (32.1%) is considered high.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 04:23 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Protagonist Therapeutics, Inc. is covered by 20 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Douglas Tsao | Barclays |
| Mayur Somaiya | BMO Capital Markets Equity Research |
| Etzer Darout | BMO Capital Markets Equity Research |